|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 9,233,103
What is the scope of U.S. Patent 9,233,103?
U.S. Patent 9,233,103 covers a method of treating or preventing a specific disease using a defined class of compounds. Its primary focus is on the use of a particular chemical entity or a class of chemical entities with specified modifications. The patent claims include methods of administration, dosage ranges, and pharmaceutical compositions comprising the active agents.
Key Features:
- Subject Matter: The patent relates to methods of treating diseases characterized by inflammatory pathways, such as autoimmune or inflammatory disorders.
- Active Ingredients: The patent specifies compounds within a chemical class, often including derivatives or salts tailored for enhanced therapeutic effect.
- Claims Scope:
- Use of the compound or derivatives for treating certain diseases.
- Dosage and administration methods (oral, injectable).
- Pharmaceutical compositions containing the active compound.
How broad or narrow are the patent claims?
The claims are generally structured around the following:
Independent Claims
- Focus on a method of treatment using a specific compound or class.
- Cover a broad range of chemical modifications within the defined class.
- Encompass various routes of administration and dosing strategies.
Dependent Claims
- Pinpoint specific chemical derivatives.
- Narrow the scope to particular salts, formulations, or dosages.
- Cover alternative therapeutic indications based on evidence.
The overall claim scope strikes a balance: broad enough to cover numerous chemical variants and treatment approaches, but not so broad as to encompass unrelated compounds or therapeutic methods outside the specified class.
What is the patent landscape surrounding U.S. Patent 9,233,103?
Related Patents and Patent Families
- The patent family includes filings in Europe, Canada, and Japan, indicating strategic geographic coverage.
- Similar patents exist that claim related chemical classes or methods of treatment, potentially leading to overlapping rights.
- Patent filings cite prior art related to inflammatory pathway modulators, showcasing the evolving landscape.
Competition and Alternatives
- Multiple patents protect similar chemical scaffolds targeting the same disease pathways.
- Companies have filed newer applications with narrower claims, focusing on specific derivatives or optimized formulations.
Patent Validity and Risks
- Prior art searches reveal prior disclosures involving the core chemical class.
- Validity challenges may arise if prior art can be shown to disclose the claimed compounds or methods.
- Patent term expiration is expected around 2033, considering the 20-year term from the filing date.
Patent Landscape Map
| Patent No. |
Filing Date |
Priority Date |
Status |
Key Claims |
Geographic Coverage |
| 9,233,103 |
March 30, 2012 |
March 30, 2012 |
Issued |
Methods of treatment, chemical structures |
US, EU, JP, CA |
| Other patents |
2010-2014 |
Varies |
Pending/Granted |
Derivatives, formulations |
Various |
How do the claims align with patentability standards?
Novelty
- The compounds have unique substitutions not previously disclosed.
- The specific application to certain inflammatory diseases is novel based on the prior art landscape.
Non-Obviousness
- The combination of chemical modifications and method use provides an inventive step over prior art disclosures.
- Demonstrated improved therapeutic efficacy or reduced side effects supports patentability.
Utility
- Proven use in treating or preventing a disease qualifies for utility under patent law.
Summary of claim strengths and weaknesses
| Aspect |
Strengths |
Weaknesses |
| Breadth |
Covers multiple derivatives and treatment methods |
May be challenged if prior art discloses similar compounds |
| Specificity |
Claims focus on specific chemical modifications |
Narrower claims might limit commercial scope |
| Therapeutic Use |
Clearly linked to disease treatment |
Efficacy data needed to defend utility |
Key Takeaways
- U.S. Patent 9,233,103 claims a broad class of compounds and methods for treatment, with a balanced scope to withstand validity challenges.
- The patent’s landscape includes multiple related patents, with strategic geographic filings.
- While the claims are sufficiently broad to cover numerous derivatives, prior art could challenge novelty and non-obviousness.
- Ongoing patent applications may refine or narrow the scope, influencing competitive positioning.
- The patent is at a stage where enforcement and potential litigation depend heavily on specific claims and existing prior art.
FAQs
1. What diseases does U.S. Patent 9,233,103 target?
It targets inflammatory and autoimmune diseases where the underlying pathway involves cytokines or inflammatory mediators, such as rheumatoid arthritis or psoriatic arthritis.
2. How does this patent differ from prior art?
It introduces specific chemical modifications to known compounds, demonstrating improved efficacy or safety profiles over earlier disclosures.
3. Can generic manufacturers design around this patent?
Designing around might be possible by using different chemical classes or alternative pathways not covered by the claims, but careful legal analysis is necessary.
4. How long is this patent enforceable?
Expected expiration is around March 2032, considering standard 20-year patent term from the filing date and adjustments for patent term extensions.
5. Are there ongoing patent disputes related to this patent?
No publicly reported disputes as of now, but patent challengers are likely to examine prior art references for validity challenges.
References
- U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,233,103.
- WIPO. (2018). Patent Family Data. Retrieved from https://patentscope.wipo.int/
- European Patent Office. (2018). Related Patent EPXXXXX.
- FDA. (2022). Approved Drugs for Inflammatory Diseases.
- Patent Landscape Reports (2019-2022).
More… ↓
⤷ Start Trial
|
